OR WAIT null SECS
November 17, 2010
To find out about the regulatory, formulation, and manufacturing considerations involved in developing a new device to deliver a drug, Equipment and Processing Report talked to Paul Wotton, CEO of Antares Pharma.
November 11, 2010
Eli Lilly Acquires Avid Radiopharmaceuticals; EMA Recruiting New Director; and More
The market for orally disintegrating and fast dissolving tablets could exceed revenues of $13 billion by 2015 based on upward global growth trends, according to a report from Technology Catalysts International, a technology transfer and business consulting firm based in Virginia.
November 04, 2010
sanofi acquires BMP Sunstone; DCAT Names President; and More.
November 02, 2010
Abuse-deterrent combination drugs represent a niche area in formulation development.
USP is working to ensure quality standards and to increase public information.
An analysis of the approaches and tools used to tackle the problem of poorly soluble drugs.
As technology advances, industry's needs are growing.
Scientists and practitioners must work together for the overall good of the patient.
The authors describe the development of an inclusion complex of GLZ and formulated an extended-release dosage form based on osmotic technology.